Decision makers increasingly request evidence on the real-world cost effectiveness of a new
treatment. There is, however, a lack of practical guidance on how to conduct an economic …

Objective To investigate whether the prices of new anticancer drugs correlated with their
relative benefit despite negotiation. Design Retrospective cross-sectional study correlating …

Background This study aimed to describe the clinical and cost-effectiveness evidence
supporting reimbursement decisions of new cancer drugs and analyze the influence of trial …

Background. Scientific advances have led to the discovery of novel treatments with high
prices. The cost to publicly fund high-cost drugs may threaten the sustainability of drug …

Randomised phase III trials are the ideal setting for prospective collection of economic and
health related quality of life (HRQL) data. Many studies combine prospective clinical data …

Rising health care costs, expensive new health care technologies and increasing patient
expectations are placing huge pressures on the publicly funded health care system in …

Introduction More than 8 times as many new cancer drugs were approved during 2005–
2015 as were approved during 1975–1985 (66 vs. 8). The average annual 2010–2014 …

In order to decide whether a new treatment should be used in patients, a robust estimate of
efficacy and toxicity is no longer sufficient. As a result of increasing healthcare costs across …

Background Cost-effectiveness evidence is increasingly considered in the reimbursement
decisions of pharmaceuticals. In some jurisdictions such as the UK and Canada …

Randomized phase III clinical trials provide important information on the efficacy of new
pharmaceutical agents for cancer patients. Policy makers are showing increased interest in …